A UK healthcare provider has committed to bolstering research into eczema treatment by pledging sustained funding to drive scientific breakthroughs. Circle Health Group, which operates The Hampshire Clinic in Basingstoke, has announced it will donate £10,000 annually to the British Skin Foundation (BSF), with the explicit goal of supporting studies into how eczema impairs the skin barrier and exploring new treatment strategies.
Adam Busby, Circle Health’s Chief Clinical and Quality Officer, emphasized the real-world burden of eczema: “Eczema is a debilitating condition that impacts hundreds of thousands of people across the UK.” The donation, he explained, will enable the British Skin Foundation to undertake “first-of-its-kind research” into the mechanisms through which eczema damages the barrier function of the skin, with hopes that it will inform better clinical prevention and intervention strategies—ultimately laying the groundwork for more effective eczema treatment.
Matthew Patey OBE, CEO of the British Skin Foundation, welcomed the support, acknowledging that despite advances in dermatology, many gaps remain in translating research into improved outcomes for patients. This partnership aims to accelerate that conversion of discovery into difference.
Broader momentum in eczema research funding
Circle Health’s commitment comes at a moment of growing investment and scientific interest in eczema treatment and prevention across the UK and globally.
At the University of Exeter, researchers have secured a £3.3 million grant over five years from the Medical Research Council to explore how fungal microbes (particularly Malassezia) interact with the immune system in people with eczema, and whether interventions in the skin microbiome might help curb disease severity. This work could pave the way for novel biologic or microbial-based therapies.
Meanwhile, the National Eczema Society has launched its inaugural research grant call for 2025/26, offering fully funded PhD studentships, innovation grants (up to £10,000), and pump-priming grants (up to £30,000) to stimulate early-stage discoveries in eczema care. To date, investigators such as Professor Carsten Flohr of King’s College London have been awarded pump-priming support to explore under-studied perspectives—such as women’s lived experience of eczema, particularly in relation to pregnancy and reproductive health.
At the University of Nottingham, researchers have initiated the “Keep Control of Eczema” study, recruiting eczema patients for a randomized trial to determine optimal durations for steroid-cream use during flare-ups. The study addresses a common clinical dilemma: whether using topical steroids a little longer may lead to more stable control without undue side effects.
Advances in eczema treatment: new therapies and breakthroughs
The research backing is being mirrored by rapid advances in therapeutic innovation. Recent years have seen multiple new or emerging eczema treatments approved or in late-stage trials:
In late 2024, the U.S. Food and Drug Administration approved Nemluvio (a biologic IL-31 inhibitor) and Vtama (a nonsteroidal topical cream) for atopic dermatitis patients whose disease is persistent under conventional therapy.
Lebrikizumab, a monoclonal antibody targeting interleukin-13 (IL-13), has shown promising long-term results: a recent 52-week study suggested that even patients with delayed response by 16 weeks can still achieve substantial skin clearance and itch relief.
Several Janus kinase (JAK) inhibitors—such as abrocitinib, upadacitinib, and topical ruxolitinib—are being assessed or used clinically for eczema, particularly for moderate to severe cases. In the UK, a key candidate, delgocitinib, a topical JAK inhibitor for chronic hand eczema, is under review by NICE (UK’s health technology assessment authority) and may become available through the NHS.
In the U.S., regulatory momentum continues: in September 2025, the FDA approved Opzelura, a topical JAK inhibitor, for pediatric patients aged 2 to 11, offering a non-steroidal option for children.
A novel immune-modulating agent, rezpegaldesleukin, has generated excitement following a mid-stage trial (REZOLVE-AD) in which patients receiving subcutaneous injections showed 53–61 % improvement in Eczema Area and Severity Index (EASI) scores at 16 weeks compared to 31 % in placebo arms. Over one-third of participants achieved at least a 75 % reduction in symptoms. The drug’s mechanism—stimulating regulatory T cells—represents a new immunologic biology in eczema therapy.
In the background, other investigational molecules such as gusacitinib (a pan-JAK/SYK inhibitor) are being evaluated as potential oral treatments for refractory eczema cases.
These advances collectively expand the therapeutic arsenal beyond traditional corticosteroids and emollients, offering hope for more precise, durable, and safe eczema treatment options.
Why Circle Health’s pledge matters
While high-profile drug trials often capture headlines, foundational research—like that targeted at the skin barrier, the microbiome, or immune triggers—is essential. The Circle Health Group’s annual £10,000 commitment may seem modest in the context of large biomedical budgets, but such reliable funding can help seed riskier, early-stage investigations that might otherwise struggle to find support.
By channeling resources to the British Skin Foundation and partnering with academic and clinical teams across the UK, this effort helps ensure that patients’ lived experience, barrier biology, fungal triggers, and new immunologic therapies are not left behind. In aggregate with national and international funding trends, it underscores a pivotal shift: eczema is no longer viewed simply as a nuisance skin complaint, but as a complex immune–barrier disorder deserving of strategic investment and innovation.
As these combined research efforts bear fruit, patients and clinicians alike may hope for more personalized, effective, and safe eczema treatment pathways in the coming years.
